Total number of patients with Crohn's disease of ulcerative colitis to receive biologic treatments (infliximab, adalumimab) between 2016 and 2020 inclusive who were
1. White New Zealander
2. Maori
3. Asian (Ideally separated into South Asian and East Asian)
4. Pacific Islanders by each ethnicity separately.
Last modified:
